Glenmark receives USFDA nod for skin disease cream

PTI New Delhi | Updated on March 12, 2018 Published on January 28, 2013

Drug firm Glenmark Pharmaceuticals today said it has received the US health regulator’s approval to market Mupirocin Calcium Cream, used for treating skin diseases, in the American market.

Glenmark Generics Inc, a subsidiary of Glenmark Generics Ltd, has been granted a final abbreviated new drug approval from the United States Food and Drug Administration (USFDA) for Mupirocin Calcium Cream USP 2 per cent, Glenmark Pharmaceuticals said in a statement.

“Glenmark will commence shipping immediately,” it added.

Glenmark Generics Ltd (GGL) is a subsidiary of Glenmark Pharmaceuticals Ltd and has a global presence, including in North America.

Mupirocin Calcium Cream is indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm2 in area) due to susceptible strains of S aureus and S pyogenes.

According to IMS health sales data for the 12-month period ending September 2012, the product generated sales of $56.5 million.

Shares of Glenmark Pharmaceuticals were trading at Rs 509 per share on the BSE in afternoon trade, down 0.79 per cent from their precious close.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on January 28, 2013
This article is closed for comments.
Please Email the Editor